Niusule Biotech, a Chinese maker of veterinary medicines and human nutraceuticals, has reported a sharp rise in first-quarter revenue and earnings after its acquisition of Tianjin Behigh. In the three months to March 31st, the company made a net profit of $592,486, up from a $441,156 loss in the ...
Please Login to read the full article.
